A Pharmacist’s Perspectives on Emerging Trends in AML
Date: Wednesday, August 20, 2025
Time: 2 pm & 5 pm EST
In acute myeloid leukemia (AML), mutation testing at diagnosis can mean the difference between timely access to targeted therapies and missed opportunities. For mutations linked to the menin pathway, early identification is essential for guiding treatment sequencing and eligibility for emerging therapies.
In this special double-feature session, Jessica Freydman, PharmD, BCOP will share a pharmacist’s perspective on integrating mutation testing into AML workflows, interpreting results in treatment planning, and managing patients on novel targeted therapies in community settings.
What You’ll Learn
- How and when to incorporate early mutation testing into AML workflows
- Key biomarkers to identify, including those tied to the menin pathway
- Strategies to interpret results and guide sequencing decisions
- Approaches to overcoming access barriers for targeted therapies
- Best practices for managing toxicities and ensuring adherence
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
New Horizon for ALK-rearranged NSCLC Patients: lorlatinib
October 27, 2025 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Bringing Bispecifics and 505(b)(2) Medications Into Practice
October 28, 2025 | 5:00 PM
